{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:39:30Z","timestamp":1785469170609,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.seizure.2020.03.015","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T01:07:05Z","timestamp":1587085625000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre"],"prefix":"10.1016","volume":"79","author":[{"given":"Philippa","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Shanmugarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Tsironis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Brockington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"March (9566)","key":"10.1016\/j.seizure.2020.03.015_bib0005","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"March (8169)","key":"10.1016\/j.seizure.2020.03.015_bib0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(80)91159-9","article-title":"Teratogenic potential of valproic acid","volume":"1","author":"Brown","year":"1980","journal-title":"Lancet"},{"issue":"November (3)","key":"10.1016\/j.seizure.2020.03.015_bib0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/ajmg.1320190308","article-title":"The fetal valproate syndrome","volume":"19","author":"Diliberti","year":"1984","journal-title":"Am J Med Genet"},{"issue":"November (11)","key":"10.1016\/j.seizure.2020.03.015_bib0020","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/jnnp.2003.029132","article-title":"The longer term outcome of children born to mothers with epilepsy","volume":"75","author":"Adab","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"April (16)","key":"10.1016\/j.seizure.2020.03.015_bib0025","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"issue":"October (10)","key":"10.1016\/j.seizure.2020.03.015_bib0030","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1528-1167.2010.02668.x","article-title":"Early cognitive development in children born to women with epilepsy: a prospective report","volume":"51","author":"Bromley","year":"2010","journal-title":"Epilepsia"},{"issue":"July (7)","key":"10.1016\/j.seizure.2020.03.015_bib0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/adc.2009.176990","article-title":"Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine","volume":"96","author":"Cummings","year":"2011","journal-title":"Arch Dis Child"},{"issue":"June (6)","key":"10.1016\/j.seizure.2020.03.015_bib0040","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp-2012-304270","article-title":"The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs","volume":"84","author":"Bromley","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10091","key":"10.1016\/j.seizure.2020.03.015_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(17)31866-4","article-title":"France bans sodium valproate use in case of pregnancy","volume":"390","author":"Casassus","year":"2017","journal-title":"Lancet"},{"issue":"August","key":"10.1016\/j.seizure.2020.03.015_bib0050","doi-asserted-by":"crossref","first-page":"k3625","DOI":"10.1136\/bmj.k3625","article-title":"Valproate, women, and exceptional circumstances","volume":"362","author":"Angus-Leppan","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2020.03.015_bib0055","series-title":"Guidance document on valproate use in women and girls of childbearing years","author":"Shakespeare","year":"2019"},{"issue":"June (6)","key":"10.1016\/j.seizure.2020.03.015_bib0060","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/humrep\/deu056","article-title":"Too old to have children? Lessons from natural fertility populations","volume":"29","author":"Eijkemans","year":"2014","journal-title":"Hum Reprod"},{"key":"10.1016\/j.seizure.2020.03.015_bib0065","series-title":"NICE","year":"2017"},{"key":"10.1016\/j.seizure.2020.03.015_bib0070","series-title":"Report of the audit in Sheffield primary care of the implementation of the valproate pregnancy prevention programme (PREVENT","author":"Storkes","year":"2019"},{"key":"10.1016\/j.seizure.2020.03.015_bib0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fneur.2019.00139","article-title":"Valproate MHRA guidance: limitations and opportunities","volume":"10","author":"Watkins","year":"2019","journal-title":"Front Neurol"},{"issue":"April (681)","key":"10.1016\/j.seizure.2020.03.015_bib0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3399\/bjgp19X701897","article-title":"Valproate and the pregnancy prevention programme: exceptional circumstances","volume":"69","author":"Watkins","year":"2019","journal-title":"Br J Gen Pract"},{"issue":"August (2)","key":"10.1016\/j.seizure.2020.03.015_bib0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jnnp.73.2.121","article-title":"Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management","volume":"73","author":"Bauer","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"September (3)","key":"10.1016\/j.seizure.2020.03.015_bib0090","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/epi4.12228","article-title":"Valproic acid utilization among girls and women in Stockholm: impact of regulatory restrictions","volume":"3","author":"Karlsson Lind","year":"2018","journal-title":"Epilepsia Open"},{"issue":"August","key":"10.1016\/j.seizure.2020.03.015_bib0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.seizure.2019.07.001","article-title":"Valproate utilisation trends among girls and women from 2013 to 2018","volume":"70","author":"Puteikis","year":"2019","journal-title":"Seizure"},{"issue":"February (2)","key":"10.1016\/j.seizure.2020.03.015_bib0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-0404.2009.01260.x","article-title":"Changing patterns of antiepileptic drug use in pregnant Australian women","volume":"121","author":"Vajda","year":"2010","journal-title":"Acta Neurol Scand"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:54:08Z","timestamp":1761011648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120301023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"alternative-id":["S1059131120301023"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.03.015","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact and challenges of the 2018 MHRA statement on the use of sodium valproate in women of childbearing age during the first year of implementation, in a UK epilepsy centre","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}